MERCK Kommanditgesellschaft auf Aktien (0O14) - Net Assets
Based on the latest financial reports, MERCK Kommanditgesellschaft auf Aktien (0O14) has net assets worth €29.00 Billion EUR as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€50.93 Billion) and total liabilities (€21.93 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €29.00 Billion |
| % of Total Assets | 56.94% |
| Annual Growth Rate | 15.22% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 8.85 |
MERCK Kommanditgesellschaft auf Aktien - Net Assets Trend (2020–2024)
This chart illustrates how MERCK Kommanditgesellschaft auf Aktien's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MERCK Kommanditgesellschaft auf Aktien (2020–2024)
The table below shows the annual net assets of MERCK Kommanditgesellschaft auf Aktien from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €29.99 Billion | +12.08% |
| 2023-12-31 | €26.75 Billion | +2.88% |
| 2022-12-31 | €26.00 Billion | +21.43% |
| 2021-12-31 | €21.42 Billion | +25.85% |
| 2020-12-31 | €17.02 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to MERCK Kommanditgesellschaft auf Aktien's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 52.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €22.09 Billion | 73.84% |
| Other Components | €7.83 Billion | 26.16% |
| Total Equity | €29.91 Billion | 100.00% |
MERCK Kommanditgesellschaft auf Aktien Competitors by Market Cap
The table below lists competitors of MERCK Kommanditgesellschaft auf Aktien ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Telkom Indonesia (Persero) Tbk PT
JK:TLKM
|
$17.99 Billion |
|
OMV Aktiengesellschaft
VI:OMV
|
$18.01 Billion |
|
TELUS
F:BCZ
|
$18.01 Billion |
|
Gold Circuit Electronics Ltd
TW:2368
|
$18.02 Billion |
|
Merck KGaA
XETRA:MRK
|
$17.91 Billion |
|
JD HEALTH INTL LTD
F:8ZN
|
$17.90 Billion |
|
Divi's Laboratories Limited
NSE:DIVISLAB
|
$17.88 Billion |
|
Publicis Groupe SA
PA:PUB
|
$17.87 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MERCK Kommanditgesellschaft auf Aktien's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 26,680,000,000 to 29,912,000,000, a change of 3,232,000,000 (12.1%).
- Net income of 2,777,000,000 contributed positively to equity growth.
- Dividend payments of 284,000,000 reduced retained earnings.
- Other factors increased equity by 739,000,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €2.78 Billion | +9.28% |
| Dividends Paid | €284.00 Million | -0.95% |
| Other Changes | €739.00 Million | +2.47% |
| Total Change | €- | 12.11% |
Book Value vs Market Value Analysis
This analysis compares MERCK Kommanditgesellschaft auf Aktien's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.72x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.04x to 1.72x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | €38.98 | €118.60 | x |
| 2021-12-31 | €49.08 | €118.60 | x |
| 2022-12-31 | €59.63 | €118.60 | x |
| 2023-12-31 | €61.36 | €118.60 | x |
| 2024-12-31 | €68.80 | €118.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MERCK Kommanditgesellschaft auf Aktien utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.28%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.13%
- • Asset Turnover: 0.41x
- • Equity Multiplier: 1.72x
- Recent ROE (9.28%) is below the historical average (11.75%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 11.73% | 11.33% | 0.42x | 2.47x | €292.40 Million |
| 2021 | 14.32% | 15.52% | 0.43x | 2.13x | €921.20 Million |
| 2022 | 12.83% | 14.96% | 0.46x | 1.87x | €733.30 Million |
| 2023 | 10.58% | 13.45% | 0.43x | 1.82x | €156.00 Million |
| 2024 | 9.28% | 13.13% | 0.41x | 1.72x | €-214.20 Million |
Industry Comparison
This section compares MERCK Kommanditgesellschaft auf Aktien's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,209,513,458
- Average return on equity (ROE) among peers: -158.34%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MERCK Kommanditgesellschaft auf Aktien (0O14) | €29.00 Billion | 11.73% | 0.76x | $17.92 Billion |
| Allergy Therapeutics (AGY) | $37.77 Million | -36.48% | 0.93x | $7.85 Million |
| Animalcare Group Plc (ANCR) | $15.38 Million | 6.75% | 0.65x | $2.80 Million |
| Alliance Pharma plc (APH) | $7.50 Million | 8.81% | 3.77x | $4.26 Million |
| Beximco Pharmaceuticals Limited (BXP) | $8.25 Billion | 4.28% | 0.45x | $2.31 Million |
| Celadon Pharmaceuticals PLC (CEL) | $99.03K | -1412.59% | 37.89x | $112.25K |
| Chill Brands Group PLC (CHLL) | $-1.23 Million | 0.00% | 0.00x | $33.40K |
| Eco Animal Health Group Plc (EAH) | $95.31 Million | 7.70% | 0.23x | $812.15K |
| HUTCHMED China Ltd (HCM) | $68.81 Million | -9.98% | 1.32x | $23.00 Million |
| Hikma Pharmaceuticals PLC (HIK) | $2.41 Billion | 6.43% | 0.81x | $37.16 Million |
About MERCK Kommanditgesellschaft auf Aktien
Merck KGaA operates as a science and technology company in Germany. The company's Life Science segment offers a range of products, including reagents, consumable, devices, instruments, software, and services for scientific discovery, as well as provides lab water instruments, consumables and services, microbiology and biomonitoring, products, test assays, analytical reagents, and flow cytometry k… Read more